Literature DB >> 30429697

Severe Neuropathic Pain With Concomitant Administration of Vincristine and Posaconazole.

Mark John-Yung Lin, Megan Rose Paul, Dennis John Kuo.   

Abstract

Vincristine is a chemotherapeutic agent with a potential toxicity of sensorimotor peripheral neuropathy. Patients receiving chemotherapy are in an immunocompromised state and may require antifungal agents. Triazole antifungals are known inhibitors of cytochrome P450 (CYP) enzymes. Vincristine is a known CYP3A4 and CYP3A5 substrate, and concomitant administration with fluconazole or voriconazole has been reported to increase vincristine toxicity and peripheral neuropathy, but there is limited literature on posaconazole in this regard. This 5-year-old girl with pre-B-cell acute lymphoblastic leukemia received vincristine while receiving posaconazole for a mucormycosis infection and developed unexpectedly severe peripheral neuropathy. After recovery, the child continued on mucormycosis prophylaxis with posaconazole with instructions to hold for 2 days before and on the day of vincristine administration. This case illustrates the potentiating effect that posaconazole had on vincristine-associated neurotoxicity, and our approach to mitigating that negative interaction.

Entities:  

Keywords:  CYP3A4; leukemia; neurotoxicity; posaconazole; vincristine

Year:  2018        PMID: 30429697      PMCID: PMC6213623          DOI: 10.5863/1551-6776-23.5.417

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  13 in total

Review 1.  Pharmacodynamic implications for use of antifungal agents.

Authors:  Russell E Lewis
Journal:  Curr Opin Pharmacol       Date:  2007-07-09       Impact factor: 5.547

Review 2.  Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.

Authors:  J D Chan
Journal:  Pharmacotherapy       Date:  1998 Nov-Dec       Impact factor: 4.705

3.  Vincristine toxicity with co-administration of fluconazole: Long-term concerns.

Authors:  Jennifer Thackray; Krisoula Spatz; Peter G Steinherz
Journal:  Pediatr Blood Cancer       Date:  2017-05-24       Impact factor: 3.167

Review 4.  Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

Authors:  Michael J Dolton; John E Ray; Deborah Marriott; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

Review 5.  Vincristine-induced peripheral neuropathy in pediatric cancer patients.

Authors:  Erika Mora; Ellen M Lavoie Smith; Clare Donohoe; Daniel L Hertz
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

6.  Posaconazole-increased vincristine neurotoxicity in a child: a case report.

Authors:  Céline Eiden; Gilles Palenzuela; Dominique Hillaire-Buys; Geneviève Margueritte; Marylène Cociglio; Sylvie Hansel-Esteller; Hélène Peyriere
Journal:  J Pediatr Hematol Oncol       Date:  2009-04       Impact factor: 1.289

7.  Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.

Authors:  Christopher C Porter; Amy E Carver; Edythe A Albano
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

8.  Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study.

Authors:  D Wexler; R Courtney; W Richards; C Banfield; J Lim; M Laughlin
Journal:  Eur J Pharm Sci       Date:  2004-04       Impact factor: 4.384

9.  Posaconazole-vincristine coadministration triggers seizure in a young female adult: a case report.

Authors:  Dalia A Hamdy; Hager El-Geed; Samah El-Salem; Manal Zaidan
Journal:  Case Rep Hematol       Date:  2012-03-14

10.  Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia.

Authors:  Lihua Yang; Lihua Yu; Xinxin Chen; Yanqun Hu; Bin Wang
Journal:  Med Sci Monit       Date:  2015-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.